Jan O. Johansson

2.0k total citations
51 papers, 1.3k citations indexed

About

Jan O. Johansson is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Jan O. Johansson has authored 51 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 13 papers in Surgery and 13 papers in Oncology. Recurrent topics in Jan O. Johansson's work include Protein Degradation and Inhibitors (22 papers), Cholesterol and Lipid Metabolism (11 papers) and Diabetes Treatment and Management (8 papers). Jan O. Johansson is often cited by papers focused on Protein Degradation and Inhibitors (22 papers), Cholesterol and Lipid Metabolism (11 papers) and Diabetes Treatment and Management (8 papers). Jan O. Johansson collaborates with scholars based in United States, United Kingdom and Sweden. Jan O. Johansson's co-authors include Ewelina Kulikowski, Michael Sweeney, Norman C.W. Wong, Torbjörn U.C. Järbe, Gregory G. Schwartz, Kausik K. Ray, John K. Bielicki, Stephen J. Nicholls, Kamyar Kalantar‐Zadeh and Bengt G. Henriksson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Circulation.

In The Last Decade

Jan O. Johansson

48 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan O. Johansson United States	20	632	274	271	180	159	51	1.3k
Xiaoping Li China	21	783 1.2×	115 0.4×	104 0.4×	194 1.1×	161 1.0×	89	1.6k
Joseph Manetta United States	13	668 1.1×	103 0.4×	375 1.4×	73 0.4×	96 0.6×	19	1.5k
Birgitte Ursø Denmark	20	769 1.2×	219 0.8×	342 1.3×	72 0.4×	282 1.8×	25	1.6k
Phong Nguyen United States	23	539 0.9×	69 0.3×	200 0.7×	106 0.6×	131 0.8×	51	1.2k
A.L. García-Otín Spain	21	323 0.5×	363 1.3×	230 0.8×	70 0.4×	201 1.3×	50	1.1k
Bonnie C. Miller United States	14	436 0.7×	228 0.8×	333 1.2×	110 0.6×	130 0.8×	24	954
Myron L. Toews United States	23	757 1.2×	71 0.3×	192 0.7×	278 1.5×	66 0.4×	71	1.3k
Nicole Simonavicius Germany	8	675 1.1×	134 0.5×	122 0.5×	176 1.0×	70 0.4×	8	1.5k
Graeme L. Fraser United States	22	490 0.8×	206 0.8×	223 0.8×	223 1.2×	310 1.9×	37	1.6k
Noriyoshi Hashimoto Japan	14	781 1.2×	59 0.2×	197 0.7×	163 0.9×	105 0.7×	25	1.9k

Countries citing papers authored by Jan O. Johansson

Since Specialization

Citations

This map shows the geographic impact of Jan O. Johansson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan O. Johansson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan O. Johansson more than expected).

Fields of papers citing papers by Jan O. Johansson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan O. Johansson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan O. Johansson. The network helps show where Jan O. Johansson may publish in the future.

Co-authorship network of co-authors of Jan O. Johansson

This figure shows the co-authorship network connecting the top 25 collaborators of Jan O. Johansson. A scholar is included among the top collaborators of Jan O. Johansson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan O. Johansson. Jan O. Johansson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yassine, Hussein N., Bernadette O’Donovan, Lance A. Johnson, et al.. (2025). APOE-Targeted Therapeutics for Alzheimer's Disease. Journal of Neuroscience. 45(46). e1388252025–e1388252025. 1 indexed citations

Johansson, Jan O., Bengt Winblad, Daniel M. Michaelson, et al.. (2024). The ABCA1 agonist CS6253 shows favorable safety and pharmacokinetics in IND‐enabling toxicology and Phase 1 human studies aimed at the indication of Alzheimer’s disease. Alzheimer s & Dementia. 20(S6).

Gilham, Dean, Sylwia Wasiak, Brooke D. Rakai, et al.. (2023). Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment. Biomedicines. 11(6). 1663–1663. 6 indexed citations

Valencia‐Olvera, Ana C., Deebika Balu, Jason York, et al.. (2023). A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3. Alzheimer s Research & Therapy. 15(1). 216–216. 7 indexed citations

Wasiak, Sylwia, Laura Tsujikawa, Dean Gilham, et al.. (2022). Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. Atherosclerosis. 364. 10–19. 12 indexed citations

Fu, Li, Sylwia Wasiak, Laura Tsujikawa, et al.. (2022). Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy. Pharmacology Research & Perspectives. 10(3). e00949–e00949. 9 indexed citations

Moulton, Matthew J., Scott Barish, Isha Ralhan, et al.. (2021). Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer’s disease–associated genes. Proceedings of the National Academy of Sciences. 118(52). 106 indexed citations

Cummings, Jeffrey L., Gregory G. Schwartz, Stephen J. Nicholls, et al.. (2021). Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. Journal of Alzheimer s Disease. 83(4). 1703–1715. 21 indexed citations

Nicholls, Stephen J., Gregory G. Schwartz, Kevin A. Buhr, et al.. (2021). Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovascular Diabetology. 20(1). 13–13. 56 indexed citations

10.

Ray, Kausik K., Stephen J. Nicholls, Kevin A. Buhr, et al.. (2020). Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes. JAMA. 323(16). 1565–1565. 112 indexed citations

11.

Hafiane, Anouar, Jan O. Johansson, & Jacques Genest. (2019). ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux–Dependent Mechanism. Canadian Journal of Cardiology. 35(6). 770–781. 14 indexed citations

12.

Wasiak, Sylwia, Dean Gilham, Christopher Halliday, et al.. (2019). Abstract 671: Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients. Arteriosclerosis Thrombosis and Vascular Biology. 1 indexed citations

13.

Tsujikawa, Laura, Li Fu, Brooke D. Rakai, et al.. (2019). APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS. Journal of the American College of Cardiology. 73(9). 2063–2063. 1 indexed citations

14.

Tsujikawa, Laura, Li Fu, Christopher Halliday, et al.. (2019). Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clinical Epigenetics. 11(1). 102–102. 90 indexed citations

15.

Ray, Kausik K., Stephen J. Nicholls, Jan O. Johansson, et al.. (2018). Abstract 13189: Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study. Circulation. 1 indexed citations

16.

Boehm‐Cagan, Anat, Dror Harats, Aviv Shaish, et al.. (2016). Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins. PLoS ONE. 11(11). e0166195–e0166195. 26 indexed citations

17.

Wong, Norman C.W., et al.. (2015). RVX-208 a selective bromodomain extra-terminal protein inhibitor reduces mace in patients with high residual risks of cardiovascular disease, a post-hoc analysis. Atherosclerosis. 241(1). e8–e8.

18.

Hafiane, Anouar, John K. Bielicki, Jan O. Johansson, & Jacques Genest. (2014). Apolipoprotein E derived HDL mimetic peptide ATI-5261 promotes nascent HDL formation and reverse cholesterol transport in vitro. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1841(10). 1498–1512. 23 indexed citations

19.

Johansson, Jan O., Torbjörn U.C. Järbe, & Bengt G. Henriksson. (1975). Acute and subchronic influences of tetrahydrocannabinols on water and food intake, body weight, and temperature in rats.. PubMed. 5(1-2). 17–27. 17 indexed citations

20.

Järbe, Torbjörn U.C., Jan O. Johansson, & Bengt G. Henriksson. (1975). Δ9-Tetrahydrocannabinol and pentobarbital as discriminative cues in the Mongolian gerbil (Meriones unguiculatus). Pharmacology Biochemistry and Behavior. 3(3). 403–410. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact